Business
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that on Thursday, September 4, 2025, from 2:00 to 4:00 p.m. ET, MolDX-participating Medicare Administrative Contractors (MACs)—Palmetto GBA, CGS Administrators, Noridian Healthcare Solutions, and WPS Government Health Administrators—will convene a MolDX Contractor Advisory Committee (CAC) Meeting of medic
About this update from Lucid Group, Inc.
[{"type":"text","content":"Virtual public CAC meeting to be held September 4, 2025, at 2:00 p.m. ET","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that on Thursday, September 4, 2025, from 2:00 to 4:00 p.m. ET, MolDX-participating Medicare Administrative Contractors (MACs)—Palmetto GBA, CGS Administrators, Noridian Healthcare Solutions, and WPS Government Health Administrators—will convene a MolDX Contractor Advisory Committee (CAC) Meeting of medical experts as a critical step in the reconsideration of Local Coverage Determination (LCD) L39256, "MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, Neoplasia," as requested by Lucid in November 2024 to secure Medicare coverage for its EsoGuard® Esophageal DNA Test.","length":891,"tagName":"p"},{"type":"image","alt":"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)","displaySize":"","headline":null,"caption":"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EIajbOKjadbArgiAenSE8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c","width":400,"height":107}},"href":"https://mma.prnewswire.com/media/2003008/Lucid_TM_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are grateful to the MolDX team for their rigorous evaluation of our clinical evidence package, which has culminated in this CAC meeting where medical experts will contribute deep...